Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update
Provident Financial Services(PFS) GlobeNewswire News Room·2024-11-12 05:05-- 27% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.50 [90% CI, 0.20-1.28]) -- -- Progressing through court-administered financial restructuring process with continued interest from multiple parties EMERYVILLE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (OTC: GRTSQ), a clinical-stage biotechnolo ...